Unii-7D0yb67S97

生物活性体内研究 Unii-7D0yb67S97 试剂级价格

Unii-7D0yb67S97

CAS号:332348-12-6
英文名:Unii-7D0yb67S97
中文名:Unii-7D0yb67S97
CBNumber:CB62496133
分子式:
分子量:0
MOL File:Mol file

Unii-7D0yb67S97化学性质

储存条件 :Store at 4°C, do not freeze
形态 :Liquid
颜色 :Colorless to light yellow
水溶解性 :Soluble in water

Unii-7D0yb67S97性质、用途与生产工艺

生物活性 Abatacept (CTLA4lg) 是一种可溶性融合蛋白，由人 CTLA4 的胞外结构域和人 IgG1 Fc 部分的片段 (铰链，CH2 和 3 结构域) 组成。Abatacept 是选择性 T 细胞共刺激调节剂，也是一种用于自身免疫性疾病的蛋白药物。

体内研究

Abatacept reduces paw edema, and the SC Multiple-dose group shows significantly greater (t _obs = 2.50) paw edema reduction compared with the IV dose group.
Abatacept exhibits linear PK across the studied doses. The NCA clearance (CL) is 20.8 mL/day/kg, volume (V _ss ) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.
Abatacept (oral; 10 mg/kg; every 2 days) reduces the proportion of activated T cells (CD44highCD62L–) and inhibits the up-regulation of ICOS and CD71 in homozygous DO11.10 RAG-2 ^–/– BALB/c (H-2d/d) mice.

Animal Model:	Male Lewis rats (6-9 weeks old) with weights of 150-175 g
Dosage:	10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29
Administration:	IV or SC
Result:	Reduced paw edema, and the SC Multiple-dose group showed significantly greater (t _obs = 2.50) paw edema reduction compared with the IV dose group.

Animal Model:	Male Lewis rats (6-9 weeks old) with weights of 150-175 g
Dosage:	10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29 (Pharmacokinetic Study)
Administration:	IV or SC
Result:	The NCA clearance (CL) is 20.8 mL/day/kg, volume (V _ss ) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.